Orion Entered into an Agreement with Jemincare to Develop & Commercialize JMKX000623 for the Treatment of Pain
Shots:
- Jemincare to receive $15.88M up front and additional fees upon achievement of milestones & sales targets along with royalty of 8% to 15% on future sales in Orion territory. Orion will lead the development & commercialization costs & will manufacture the products including API
- Orion to get exclusive rights globally to develop & commercialize JMKX000623 in its country Ex- Greater China (mainland China, Hong Kong, Macau, and Taiwan) for acute and chronic pain & will also receive ownership to patent applications to the compound in its territory
- JMKX000623 is a potent & selective Nav1.8 blocker that has been developed by Jemincare. The therapy has received IND approval in China in Mar 2022
Ref: Globenewswire | Image: Orion
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
